Talk:Z3220040: Difference between revisions

Revision as of 12:53, 8 October 2009

Questions from Lab 10 article

What is the background to the existing problem / disease condition???

Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells

Mozobil- able to mobilise stem cells from bone marrow to blood and doesnt increase mobility of tumor cells in melonoma patients

Treatment for tumor patients- chemotherapy with autologous stem cell transplantation

Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy, 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells and some patients could not collect enough sample stem cells

Mozobil and Neupogen (filgrastim) solves the above problem Neupogen increases stem cell production in bone marrow Mozobil increases the mobility of stem cells from marrow to blood

Faculty of Medicine at the University of Utah conducted the use of above drugs- they utilized patients with proven poor stem cell mobilizers and potentially poor stem cell mobilizers Found that the majority of patients could produce 2 million stem cells and had successful transplantations

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

This study found that for improved response and survival rates from chemotherapy, stems cell must be mobilized and collected for transplantation back into the patient. However there is a risk of potential contamination of the sample by tumour cells. Those with poor stem cell mobilizers were given pleixafor as it was identified as improving stem cell collection.

@@ Line 6: / Line 6: @@
 '''Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells'''
-Mozobil- able to mobilise stem cells from bone marros to blood
+Mozobil- able to mobilise stem cells from bone marrow to blood and doesnt increase mobility of tumor cells in melonoma patients
-- doesnt increase mobility of tumor cells in melonoma patients
 Treatment for tumor patients- chemotherapy with autologous stem cell transplantation
-Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy
+Before chemotherapy- patients stem cells collected and then transplanted back into patient after chemotherapy, 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells and some patients could not collect enough sample stem cells
-- 2 million stem cell required adn can occur through multiple collection sessions, which increases the risk of comtaminating the sample with tumour cells.
-- some patients cannot collected enough sample stem cells
 Mozobil and Neupogen (filgrastim)  solves the above problem
@@ Line 23: / Line 20: @@
 '''Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization'''
+This study found that for improved response and survival rates from chemotherapy, stems cell must be mobilized and collected for transplantation back into the patient. However there is a risk of potential contamination of the sample by tumour cells. Those with poor stem cell mobilizers were given pleixafor as  it was identified as improving stem cell collection.